Allbiotech Biotechnologies has successfully completed its first production run of the Genesys V1 bioreactor, a significant advancement in precision fermentation technology.

This new bioreactor, designed for research and development, promises to deliver reliable data for experimentation and process optimisation at a fraction of the cost of traditional pharmaceutical bioreactors – approximately one-third of the average market price.

The Genesys V1 is tailored for early-stage testing and scaling up processes, addressing a critical need for affordable and efficient tools in the food-tech sector.

With a capacity of one litre, the bioreactor features a user-friendly control interface that supports remote operation, allowing researchers to concentrate on their experiments rather than navigating complex equipment.

Key technical specifications of the Genesys V1 include:

• 1-litre glass vessel for precise fermentation processes

• Double-blade stainless steel Rushton agitator for effective mixing

• Five peristaltic pumps with adjustable flow rates (0.05 to 200 ml/min) for controlled liquid addition

• Integrated air oxygenation pump with a flow rate of up to 2 L/min, eliminating the need for external pumps

• Automated cycle control and data logging capabilities to facilitate real-time monitoring and experimentation

The bioreactor’s design incorporates advanced features such as separate systems for agitation and oxygenation, enabling fine-tuning of environmental conditions.

The inclusion of a touchscreen control unit enhances user experience, making it easier for researchers and developers to access critical data and manage experiments effectively.

Pablo Goñi, founder of Allbiotech, emphasised the company’s commitment to lowering the economic barriers associated with bioreactor technology.

“A cost-optimised design, coupled with our experience in manufacturing high-tech equipment, has allowed us to realise a new generation of bioreactors," he said. "We are thus eliminating the economic barrier to entry, democratising the use of bioreactors without the need for large investments.”

The launch follows Allbiotech's successful investment round, which concluded in January 2025. Led by Daniel Palacio from Tutti Food Group, the funding attracted a diverse group of investors, including industry experts and entrepreneurs committed to advancing precision fermentation technologies.

The capital will enable Allbiotech to scale production and commercialisation efforts, with plans for a second production run slated for March.

Daniel Palacio remarked on the importance of supporting innovation in this sector, adding: “It is an exciting challenge to support an entrepreneur as unique as Pablo, who aims to promote research and development of new ingredients through precision fermentation, a technology that is increasingly utilised in sustainable food production”.

As the demand for sustainable food solutions rises, the Genesys V1 bioreactor positions itself as a vital tool for start-ups, research institutions and established companies in the food tech landscape.

By providing an affordable and efficient option for precision fermentation, Allbiotech is poised to play a significant role in the growth of cellular agriculture, contributing to the development of innovative food products that align with sustainability goals.

Allbiotech’s approach mirrors successful models in other sectors, using digital media to reach potential customers directly, thereby bypassing traditional distribution channels. This strategy is expected to enhance accessibility for innovators and researchers looking to leverage precision fermentation in their projects.